ArticleJournal of neurology2026
Mapping of motor and non-motor symptoms to 12-region dopamine transporter single-photon emission computed tomography in Parkinson's disease.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of nigral dopaminergic neurons, which substantially influences the severity of motor and non-motor symptoms. However, the relationship between the regional patterns of striatal dopaminergic loss and specific clinical manifestations remains unclear, as many prior studies relied on global or coarse regional measures without hemispheric resolution or adjustment for handedness. We comprehensively analyzed clinical features in relation to dopamine transporter single-photon emission computed tomography (DAT-SPECT) uptake across 12 atlas-based subregions in a large cohort.
methodsWe analyzed baseline DAT-SPECT data using
resultsIn patients with PD, motor symptoms were associated with reduced DAT-SPECT uptake across widespread striatal regions, with right-predominant involvement. Hyposmia was selectively associated with dopaminergic loss across all putaminal subregions, whereas the caudate regions were unaffected. Cognitive performance was associated with the left pre-ventral putamen. No region demonstrated FDR-significant associations in the healthy controls, and several symptom-DAT-SPECT relationships showed significant PD-specific interaction effects.
conclusions12-region DAT-SPECT mapping revealed symptom-specific topographical patterns of striatal dopaminergic dysfunction in drug-naïve patients with PD.
Indexed as
Identifiers
42228148What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.